Literature DB >> 31161852

Metabolic profiling for water-soluble metabolites in patients with schizophrenia and healthy controls in a Chinese population: A case-control study.

Bing Cao1, Dongfang Wang2, Zihang Pan3, Roger S McIntyre3,4, Elisa Brietzke3,5, Mehala Subramanieapillai3, Yasaman Nozari3, Jingyu Wang1,6,7.   

Abstract

Objectives: Objective measures integrated with clinical symptoms may improve early prevention and detection of schizophrenia. Herein we aim to evaluate potential water-soluble metabolic biomarkers in schizophrenia.
Methods: We recruited adults with schizophrenia (n = 113) who had not received pharmacological treatment for at least 1 month prior to enrollment and 111 age- and sex-matched healthy subjects from Weifang, Shandong province, China. All serum samples were analysed using liquid chromatography-tandem mass spectrometry coupled with a hydrophilic interaction liquid chromatography column.
Results: Eleven metabolites, namely carnitines (oleoylcarnitine, l-palmitoylcarnitine, 9-decenoylcarnitine and 2-trans,4-cis-decadienoylcarnitine), polar lipids (lysophosphatidylcholine (LPC)(P-16:0), LPC (16:0), LPC (15:0) and LPC(14:0)), amino acids (taurine and l-arginine), and organic acid (2,5-dichloro-4-oxohex-2-enedioate), separated the patients and healthy controls. Compared with healthy controls, taurine, l-palmitoylcarnitine and oleoylcarnitine levels were higher, whereas the remaining eight metabolites were lower in patients with schizophrenia. A combination of four metabolites, i.e., oleoylcarnitine, 9-decenoylcarnitine, LPC (15:0) and LPC (14:0), provided the most robust between-group separation.Conclusions: This study appears to distinguish between groups of patients and controls, which should be considered as a contribution to putative potential biomarkers. The water-soluble metabolites were determined to be significantly different between the groups in the current study, and were primarily related to cellular bioenergetics, notably oxidative stress.

Entities:  

Keywords:  Schizophrenia; biomarkers; liquid chromatography-mass spectrometry; metabolomics; psychosis

Mesh:

Substances:

Year:  2019        PMID: 31161852     DOI: 10.1080/15622975.2019.1615639

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  5 in total

1.  Evaluation of Metabolic Profiles of Patients with Anorexia Nervosa at Inpatient Admission, Short- and Long-Term Weight Regain-Descriptive and Pattern Analysis.

Authors:  Manuel Föcker; Alexander Cecil; Cornelia Prehn; Jerzy Adamski; Muriel Albrecht; Frederike Adams; Anke Hinney; Lars Libuda; Judith Bühlmeier; Johannes Hebebrand; Triinu Peters; Jochen Antel
Journal:  Metabolites       Date:  2020-12-24

Review 2.  Lysophosphatidylcholine: Potential Target for the Treatment of Chronic Pain.

Authors:  Jinxuan Ren; Jiaqi Lin; Lina Yu; Min Yan
Journal:  Int J Mol Sci       Date:  2022-07-27       Impact factor: 6.208

3.  Shorter Chain Triglycerides Are Negatively Associated with Symptom Improvement in Schizophrenia.

Authors:  Anna Tkachev; Elena Stekolshchikova; Nickolay Anikanov; Svetlana Zozulya; Aleksandra Barkhatova; Tatiana Klyushnik; Daria Petrova
Journal:  Biomolecules       Date:  2021-05-11

4.  Urinary Amine and Organic Acid Metabolites Evaluated as Markers for Childhood Aggression: The ACTION Biomarker Study.

Authors:  Fiona A Hagenbeek; Peter J Roetman; René Pool; Cornelis Kluft; Amy C Harms; Jenny van Dongen; Olivier F Colins; Simone Talens; Catharina E M van Beijsterveldt; Marjolein M L J Z Vandenbosch; Eveline L de Zeeuw; Sébastien Déjean; Vassilios Fanos; Erik A Ehli; Gareth E Davies; Jouke Jan Hottenga; Thomas Hankemeier; Meike Bartels; Robert R J M Vermeiren; Dorret I Boomsma
Journal:  Front Psychiatry       Date:  2020-03-31       Impact factor: 4.157

5.  Metabolomics approach revealed robust changes in amino acid and biogenic amine signatures in patients with schizophrenia in the early course of the disease.

Authors:  Madis Parksepp; Liisa Leppik; Kadri Koch; Kärt Uppin; Raul Kangro; Liina Haring; Eero Vasar; Mihkel Zilmer
Journal:  Sci Rep       Date:  2020-08-19       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.